Compare Corning Incorporated (GLW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Tango Therapeutics Inc. — how do they compare? Corning Incorporated trades at $135.72 (market cap $121.36B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Corning Incorporated is far larger — about 32.4× Tango Therapeutics Inc.'s market cap, and Corning Incorporated pays a 0.79% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and Tango Therapeutics Inc. for 0 Days on average.
| GLW | TNGX | |
|---|---|---|
Market Cap | $121.36B | $3.74B |
Volume | 7,874,233 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $255.79 | $32.90 |
52-Week Low | $78.03 | $7.50 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $128.24B | $2.76B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $148.52, up 0.87% with recent earnings beats and a major $3B AT&T fiber deal driving optimism. Technical indicators show bearish momentum with support at $144 and resistance at $153. The company demonstrates strong fundamental improvement with 2025 revenue reaching $15.63B and net income surging to $1.60B, though valuation multiples remain elevated with a P/E of 68.45.
GLW presents growth potential through AI infrastructure demand and fiber expansion, supported by 57% analyst buy ratings and a $171.25 price target. Key risks include patent litigation investigations and high valuation sensitivity to earnings growth. The stock offers 15% upside to consensus target but requires monitoring of legal developments and margin sustainability.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
